<DOC>
	<DOCNO>NCT01018862</DOCNO>
	<brief_summary>The purpose study compare effectiveness Investigational use allergy medication ( MP03-33 ) use treat perennial allergic rhinitis ( PAR ) placebo ( nasal spray contain medicine ) . In addition , study also compare safety effectiveness investigational use another allergy medication ( MP03-36 ) use treat perennial allergic rhinitis placebo .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Nasal Spray Treat Children With Perennial Allergic Rhinitis</brief_title>
	<detailed_description>Children Ages &gt; 6 &lt; 12 Perennial Allergic Rhinitis ( PAR )</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Azelastine</mesh_term>
	<criteria>Male female subject &gt; 6 &lt; 12 , inclusive screen visit At least 1year history PAR The parent must provide write informed consent child must provide write assent . Willing able comply study requirement The presence immunoglobulin E ( IgE ) mediate hypersensitivity dust mite , cockroach , mold , cat dog dander , confirm positive response skin prick test Visit 1 . A positive response define wheal diameter ≥5 mm large negative control skin prick test . Histamine control must also positive wheal diameter &gt; 5 mm large control . If prevailing seasonal allergy , subject must negative skin test specific allergen . Screening Visit : Have 12hour reflective TNSS least 6 possible 12 congestion score ≥2 rhinorrhea score ≥2 Visit 1 Randomization Visit : eligible entry doubleblind treatment period , subjects/caregivers must record : 1. least 3 symptom assessment ( either AM PM score ) past 3 day LeadIn Period Day Randomization : 1. 12hour reflective TNSS ≥ 6 2. 12hour reflective congestion score ≥2 rhinorrhea score ≥2 2. total seven LeadIn symptom assessment past 3 day LeadIn Period include Day Randomization ( Visit 2/Day 1 ) : 1. 12hour reflective TNSS ≥ 42 2. 12hour reflective congestion score ≥14 rhinorrhea score ≥14 Must take least 10 dos study medication placebo LeadIn Period General good health free disease concomitant treatment could interfere interpretation study result determine investigator sponsor 's medical officer Subjects receive immunotherapy injection ( antigen desensitization ) must stable maintenance regimen least 30 day first study visit ( adjustment regimen follow brief period miss injection preclude participation ) . Subjects receive sublingual immunotherapy exclude . A 6 month washout period require follow last dose sublingual immunotherapy . On nasal examination , subject superficial nasal mucosal erosion , moderate nasal mucosal erosion , nasal mucosal ulceration , nasal septum perforation ( Grade 1B 4 ) ( see section 8.1.4 ) . Other nasal disease ( ) likely affect deposition intranasal medication , acute sinusitis , rhinitis medicamentosa clinically significant polyposis nasal structural abnormality . Nasal surgery sinus surgery within previous year . Chronic sinusitis The use investigational drug within 30 day prior Visit 1 . No investigational product permit use conduct study Presence hypersensitivity drug similar azelastine either sorbitol sucralose ( Splenda® brand sweetener ) Females pregnant nursing Females childbearing potential abstinent practice medically acceptable method contraception Respiratory tract infection within two week prior Visit 1 Subjects significant pulmonary disease include asthma . Subjects intermittent asthma require shortacting inhaled bronchodilator eligible enrollment . Chronic obstructive sleep apnea syndrome ( clinical diagnosis ) Existence surgical medical condition , opinion investigator sponsor 's medical monitor , might significantly alter absorption , distribution , metabolism , excretion study drug might significantly affect subject 's ability complete trial . Clinically relevant abnormal physical finding within 1 week randomization , opinion investigator , would interfere objective study may preclude compliance study procedure Overnight absences home 3 night Family member research center private practice personnel directly involve study exclude Members family enroll study time Subjects use medication therapy could interfere symptom evaluation within time period specify ( see Section 4.0 ) . Any behavioral condition could affect subject 's ability accurately report symptom caregiver developmental delay , attention deficit disorder , autism</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>